Find a trial near you

MapLight Therapeutics is recruiting patients for IRIS, a Phase 2 clinical trial evaluating ML-004, the company’s lead clinical compound for patients with Autism Spectrum Disorder. The study will assess whether there is an impact of ML-004 treatment on the core social communication deficits and on the associated features of irritability in ASD. 

The randomized, double blind, placebo-controlled study will evaluate the efficacy and safety profile of ML-004 in up to 150 adults and adolescents with ASD. The study will be conducted in the United States, Australia, and Canada, and is fully funded by MapLight.

For more details on the study, and to find participating sites near you, visit ClinicalTrials.gov.